Interleukin 2 Receptor Subunit Alpha – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)- Pipeline Review, H2 2019’, provides in depth analysis on Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Oncology, Cardiovascular, Dermatology and Metabolic Disorders under development targeting Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)

– The report reviews Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics and enlists all their major and minor projects

– The report assesses Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Alkermes Plc

Anaveon AG

APT Therapeutics Inc

Bristol-Myers Squibb Co

Courier Therapeutics Inc

Mabtech Ltd

Medicenna Therapeutics Corp

Nektar Therapeutics

Philogen SpA”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Overview

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development

Alkermes Plc

Celgene Corp

Medicenna Therapeutics Corp

Nektar Therapeutics

Philogen SpA

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug Profiles

ALKS-4230 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APT-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

basiliximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

basiliximab biobetter - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-92252 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

daclizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darleukin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

daromun - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize IL2RB for Graft Versus Host Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Target NKG2D and IL2RA for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDNA-209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NARA-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NKTR-358 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teleukin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones

Featured News & Press Releases

Sep 11, 2018: Alkermes expands Phase l trial of ALKS 4230 for advanced solid tumors

Jul 18, 2018: Philogen receives orphan drug designation for the treatment of melanoma

May 18, 2018: EMA review of Zinbryta confirms medicine’s risks outweigh its benefits

May 08, 2018: Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus

Mar 15, 2018: TGA: Zinbryta (daclizumab) Product withdrawn after overseas reports of inflammatory brain disorders

Mar 09, 2018: EMA recommends immediate suspension and recall of s medicine Zinbryta

Mar 02, 2018: Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA (daclizumab) for Relapsing Multiple Sclerosis

Mar 02, 2018: EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders

Nov 10, 2017: EMA concludes review of Zinbryta and confirms further restrictions to reduce risk of liver damage

Nov 08, 2017: Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer 32nd Annual Meeting

Nov 07, 2017: Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting

Oct 27, 2017: PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage

Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma

Jul 10, 2017: Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London

Jul 07, 2017: EMA restricts use of multiple sclerosis medicine Zinbryta

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Alkermes Plc, H2 2019

Pipeline by Anaveon AG, H2 2019

Pipeline by APT Therapeutics Inc, H2 2019

Pipeline by Bristol-Myers Squibb Co, H2 2019

Pipeline by Courier Therapeutics Inc, H2 2019

Pipeline by Mabtech Ltd, H2 2019

Pipeline by Medicenna Therapeutics Corp, H2 2019

Pipeline by Nektar Therapeutics, H2 2019

Pipeline by Philogen SpA, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports